Home › Funds › BAKER BROS. ADVISORS LP › ARWR

BAKER BROS. ADVISORS LP position in ARWR

ARROWHEAD PHARMACEUTICALS IN · Health Care

BAKER BROS. ADVISORS LP reported holding 1,992,783 shares of ARWR (ARROWHEAD PHARMACEUTICALS IN) in its Q2 2026 13F filing — a position valued at US$162.4M, representing 0.85% of its reported portfolio and ranking #19 among its reported holdings. BAKER BROS. ADVISORS LP has disclosed ARWR holdings in 5 of the last 5 reported quarters, going back to Q2 2025.

Latest position (Q2 2026)1.99M sh
Reported value held$162.43M
Portfolio Weight0.85%
First reportedQ2 2025
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How BAKER BROS. ADVISORS LP's ARWR position evolved

BAKER BROS. ADVISORS LP first disclosed a stake in ARWR in Q2 2025 at 939,174 shares (US$14.8M). The position peaked in Q2 2026 at 1,992,783 shares, worth US$162.4M. Across 5 filings, BAKER BROS. ADVISORS LP increased the stake 2 time(s), trimmed it 1 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 1,992,783 shares valued at US$162.4M. Notable position changes include a 78% increase in Q3 2025 (shares rose 92% over the following quarter), a 30% increase in Q4 2025 (shares fell 6% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2025 939.17K $14.84M New
Q3 2025 1.67M $57.62M Add
Q4 2025 2.18M $144.44M Add
Q1 2026 1.99M $124.95M Reduce
Q2 2026 1.99M $162.43M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ARWR and 13F data

ARWR (ARROWHEAD PHARMACEUTICALS IN) is a Health Care company. 52 other funds we track also report a position in ARWR — the largest reported positions include Avoro Capital Advisors LLC (US$925.6M), FRED ALGER MANAGEMENT, LLC (US$269.1M), Siren, L.L.C. (US$139.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ARWR

All ARWR fund holders →

FAQ

How long has BAKER BROS. ADVISORS LP held ARWR?

BAKER BROS. ADVISORS LP has disclosed ARWR holdings in 5 of the last 5 reported quarters, going back to Q2 2025.

What is BAKER BROS. ADVISORS LP's current position in ARWR?

As of Q2 2026, BAKER BROS. ADVISORS LP holds 1.99M shares of ARWR (ARROWHEAD PHARMACEUTICALS IN), valued at $162.43M, representing 0.85% of its reported portfolio and ranking #19.

Has BAKER BROS. ADVISORS LP been buying or selling ARWR?

In the latest 13F filing (Q2 2026), BAKER BROS. ADVISORS LP held unchanged its position in ARWR. The position peaked in Q2 2026 at 1.99M shares.

Which other funds hold ARWR?

Other major institutional holders of ARWR include Avoro Capital Advisors LLC, FRED ALGER MANAGEMENT, LLC, Siren, L.L.C., among 52 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.